Zai Lab Limited (NASDAQ: ZLAB; HKG: 9688) announced its financial results for the third quarter of 2026, recording total revenues of USD 108.2 million versus USD 116.1 million a year earlier, with net product revenue of USD 107.6 million, up 2 % quarter‑over‑quarter, driven by Nuzyra and the June 2026 launch of xanomeline and trospium chloride, and partially offset by declining Optune revenue. The company also confirmed the closing of a USD 250.0 million gross private placement of ADSs.
Financial Highlights – Q3 2026
| Item | Q3 2026 | Q3 2025 | Change |
|---|---|---|---|
| Total Revenues | USD 108.2 million | USD 116.1 million | ≈ ‑6.8 % YoY (derived) |
| Net Product Revenue | USD 107.6 million | USD 115.4 million | +2 % QoQ; ≈ ‑6.8 % YoY (derived) |
Revenue Drivers
- Nuzyra: Growth driven by increased market coverage and penetration, serving as a primary contributor to the quarter‑over‑quarter rise in net product revenue.
- Xanomeline and Trospium Chloride: Newly launched in June 2026, the combination added incremental revenue in its first full quarters on the market.
- Optune (partial offset): Revenue declined due to shifts in the competitive landscape for glioblastoma, weighing against gains elsewhere in the portfolio.
Capital Raise – ADS Private Placement
| Item | Detail |
|---|---|
| Securities Purchase Agreement | Entered 22 Oct 2026 with certain qualified investors |
| Structure | Private placement of 11,340,000 ADSs (each ADS = 10 ordinary shares; par value USD 0.000006 per ordinary share) |
| Issue Price | USD 22.04 per ADS |
| Closing Date | 27 Oct 2026 |
| Gross Proceeds | Approximately USD 250.0 million |
| Net Proceeds | Approximately USD 241.2 million (after placement agent fees and other expenses) |
| Use of Proceeds | Fund development of pipeline assets; working capital and other general corporate purposes |
Market Impact & Outlook
- Sequential Stabilization: The +2 % quarter‑over‑quarter increase in net product revenue suggests the commercial portfolio is stabilizing despite year‑over‑year pressure and the Optune headwind.
- Launch Momentum: Early contributions from xanomeline and trospium chloride, less than two quarters post‑launch, add a new growth vector to the revenue base alongside Nuzyra’s expanding coverage.
- Strengthened Balance Sheet: Net proceeds of approximately USD 241.2 million materially bolster liquidity, explicitly earmarked for pipeline development — supporting continued investment without reliance on near‑term product cash flow.
- Investor Confidence Signal: Completing a USD 250 million placement with qualified investors at USD 22.04 per ADS demonstrates institutional appetite for the company’s strategy despite competitive pressure in glioblastoma.
- Watch Items: Continued ramp of the xanomeline/trospium launch, trajectory of Nuzyra penetration, competitive dynamics affecting Optune, and pipeline progression funded by the placement proceeds.
Forward‑Looking Statements
This brief contains forward‑looking statements regarding Zai Lab’s product revenue trajectories, launch performance, pipeline development funded by the private placement, and competitive dynamics. Actual results may differ due to risks including market adoption of newly launched products, competitive and pricing pressures (including in glioblastoma), regulatory developments, clinical trial outcomes, and general market conditions.-Fineline Info & Tech
